MWA
CYTK icon

Medallion Wealth Advisors’s Cytokinetics CYTK Stock Holding History

Medallion Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170 Buy
+2
New +$144 ﹤0.01% 1088

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Medallion Wealth Advisors's CYTK Position: Q2 2026 in Review

Medallion Wealth Advisors opened a new position in Cytokinetics (CYTK) in Q2 2026: 2 shares worth $170. The stake represents ﹤0.01% of the portfolio and ranks #1088 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Medallion Wealth Advisors held 2 shares of Cytokinetics worth $170 as of Q2 2026.
  • Cytokinetics was a new Medallion Wealth Advisors position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #1088 holding.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.